Holen Sie sich die Stockscreener-App
0.2028
15.54%
-0.0372
Schlusskurs vom Vortag:
$0.24
Offen:
$0.2033
24-Stunden-Volumen:
5.37M
Relative Volume:
0.74
Marktkapitalisierung:
$3.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.24M
KGV:
-0.023
EPS:
-8.83
Netto-Cashflow:
$-16.85M
1W Leistung:
-19.56%
1M Leistung:
-30.34%
6M Leistung:
-75.14%
1J Leistung:
-94.23%
1-Tages-Spanne:
$0.19
$0.2097
1-Wochen-Bereich:
$0.19
$0.29
52-Wochen-Spanne:
$0.19
$5.48
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Firmenname
Virpax Pharmaceuticals Inc
Sektor
Branche
Telefon
610-727-4597
Adresse
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
Vergleichen Sie VRPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.2028 | 3.67M | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.12 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.65 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.98 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.70 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.86 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Virpax Pharmaceuticals Inc Aktie (VRPX) Neueste Nachrichten
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Virpax Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:VRPX - Benzinga
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com Australia
Virpax Pharmaceuticals reports Molecular Envelope Technology human study data - TipRanks
Virpax lauds Nanomerics’ MET study with no severe side effects - Investing.com India
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan
Virpax(R) Pharmaceuticals to Present at ThinkEquity Conference - ACCESS Newswire
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Virpax reports positive study results for pain management drug - MSN
Breakthrough in Pain Relief: Virpax Pharmaceuticals Soars with US Army Collaboration - Bit Perfect Solutions
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Benzinga
Virpax reports positive study results for pain management drug By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur - TipRanks
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - StockTitan
Promising Nanotechnology Stocks To Follow TodayFebruary 11th - MarketBeat
Nanotechnology Stocks To Keep An Eye OnFebruary 08th - MarketBeat
Promising Nanotechnology Stocks To Watch TodayFebruary 06th - MarketBeat
Nanotechnology Stocks To Follow NowFebruary 05th - MarketBeat
Promising Nanotechnology Stocks To Watch Today – February 06th - Armenian Reporter
Virpax Pharmaceuticals Inc (VRPX) Stock: What the Analysts are Saying - The News Heater
Virpax Pharmaceuticals Appoints Charn Deol as Independent DirectorVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) announced on February 5, 2025, the appointment of Mr. Charn Deol as an independent director of the Company, effective immediately. Mr. D - Defense World
Virpax Pharmaceuticals appoints new independent director By Investing.com - Investing.com Australia
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax Pharmaceuticals Appoints Charn Deol as Independent Director - TipRanks
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Board Member Jay Panis Resigns - TipRanks
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Best Nanotechnology Stocks To Follow TodayJanuary 30th - MarketBeat
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
VRPXVirpax Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Clinical Trials Innovation: Virpax Leadership Takes Center Stage at Elite OCT Conference - StockTitan
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - GlobeNewswire
Virpax Pharmaceuticals Raises $6M and Signs Investor Agreements - TipRanks
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering - The Manila Times
Virpax Pharmaceuticals Closes of $6.0 Million Public Offering of Common Stock - citybiz
Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan
Virpax Pharmaceuticals Prices of $6 Million Public Offering of Common Stock - citybiz
Virpax Pharmaceuticals Announces $6 Mln Public Offering For Pain Relief Innovations - Nasdaq
Finanzdaten der Virpax Pharmaceuticals Inc-Aktie (VRPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.23%
1.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):